Best supportive care in lung cancer trials is inadequately described: a systematic review

被引:14
作者
Jack, B. [2 ,3 ]
Boland, A. [1 ]
Dickson, R. [1 ]
Stevenson, J.
Mcleod, C. [1 ]
机构
[1] Univ Liverpool, LRiG, Liverpool L69 3GE, Merseyside, England
[2] Marie Curie Palliat Care Inst, Liverpool, Merseyside, England
[3] Edge Hill Univ, Fac Hlth, Liverpool, Merseyside, England
关键词
best supportive care; lung cancer trials; QUALITY-OF-LIFE; ELDERLY-PATIENTS PTS; PHASE-III; RANDOMIZED-TRIAL; CHEMOTHERAPY; PLUS; SURVIVAL; BSC; VINORELBINE; MULTICENTER;
D O I
10.1111/j.1365-2354.2008.01064.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The objective of the paper was to identify and discuss clinical terms associated with the availability and delivery of best supportive care for patients with lung cancer in randomised controlled clinical trials. Systematic review was carried out of relevant studies without language restrictions identified through Medline, EMBASE, Science Citation Index (Web of Science and ISI Proceedings) and Cochrane Library. Reference lists of retrieved articles were also searched to identify further studies. Articles describing randomised controlled trials or systematic reviews with a comparator arm of best supportive care for patients with lung cancer were studied. Definitions of best supportive care and elements of best supportive care were reported. Included clinical studies (n = 40) did not adequately describe or outline either the components or the delivery of best supportive care for patients in lung cancer trials. None of the identified studies provided a clear definition of a patient pathway in relation to best supportive care, or a clear list of components. Clinical studies are being conducted without a clear definition of the best supportive care provided in the comparator arms of trials. Inadequate definitions mean that all direct and indirect comparisons in trials comparing active treatments with best supportive care must be interpreted with caution.
引用
收藏
页码:293 / 301
页数:9
相关论文
共 43 条
[1]  
AHMED N, 2004, COCHRANE DATABASE SY
[2]  
ALBERTI W, 1995, BRIT MED J, V311, P899
[3]   Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome [J].
Anderson, H. ;
Hopwood, P. ;
Stephens, R. J. ;
Thatcher, N. ;
Cottier, B. ;
Nicholson, M. ;
Milroy, R. ;
Maughan, T. S. ;
Falk, S. J. ;
Bond, M. G. ;
Burt, P. A. ;
Connolly, C. K. ;
McIllmurray, M. B. ;
Carmichael, J. .
BRITISH JOURNAL OF CANCER, 2000, 83 (04) :447-453
[4]  
[Anonymous], 2007, Cancer Statistics
[5]  
BONFILL X, 2001, COCHRANE DATABASE SY
[6]   Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer [J].
Brown, J ;
Thorpe, H ;
Napp, V ;
Fairlamb, DJ ;
Gower, NH ;
Milroy, R ;
Parmar, MKB ;
Rudd, RM ;
Spiro, SG ;
Stephens, RJ ;
Waller, D ;
West, P ;
Peake, MD .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7417-7427
[7]   Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer [J].
Butts, C ;
Murray, N ;
Maksymiuk, A ;
Goss, G ;
Marshall, E ;
Soulières, D ;
Cormier, Y ;
Ellis, P ;
Price, A ;
Sawhney, R ;
Davis, M ;
Mansi, J ;
Smith, C ;
Vergidis, D ;
Ellis, P ;
MacNeil, M ;
Palmer, M .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) :6674-6681
[8]   Taxanes as first-line therapy for advanced non-small cell lung cancer: A systematic review and practice guideline [J].
Chu, Q ;
Vincent, M ;
Logan, D ;
Mackay, JA ;
Evans, WK .
LUNG CANCER, 2005, 50 (03) :355-374
[9]  
Clerici M, 1998, ANN ONCOL, V9, P62
[10]   Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life [J].
Cullen, MH ;
Billingham, LJ ;
Woodroffe, CM ;
Chetiyawardana, AD ;
Gower, NH ;
Joshi, R ;
Ferry, DR ;
Rudd, RM ;
Spiro, SG ;
Cook, JE ;
Trask, C ;
Bessell, E ;
Connolly, CK ;
Tobias, J ;
Souhami, RL .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3188-3194